Imaging in Alzheimer's disease by Scheltens, Philip
lzheimer’s Disease (AD) is the epidemic of this
century. All research efforts should be combined to find
a cure for this devastating disease. Even postponing the
onset of the disease by 5 years will halve its prevalence.
Delay of institutional care will greatly diminish costs for
society. 
One of the key elements in finding a new cure is being
able to diagnose AD in its earliest form, ideally before
symptoms occur. For this, neuroimaging already plays an
important role, and this role will only increase in the com-
ing years.
Clinical findings
Typically, AD is characterized by an insidious onset of
cognitive decline, starting with deficits in episodic mem-
ory. Patients and their families complain, for example, of
forgetting recent personal and family events, losing items
around the house, and repetitive questioning. As the dis-
ease progresses, other deficits, such as aphasia, apraxia,
agnosia, visuospatial difficulties, and executive dysfunc-
tion, arise gradually. A simple test that relies on visuospa-
tial and executive abilities is the clock-drawing test, of
which a few examples are given in Figure 1, an image of
AD, avant la lettre. 
Psychological and behavioral problems such as mood dis-
orders, psychosis, agitation, and sleep disorders occur
more frequently as the disease progresses. The patient
becomes increasingly dependent on others. Clinical diag-
nosis is made using criteria, of which the McKhann 
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Neuroimaging in the early differential diagnosis of
dementia has gained considerable interest over the last
decade. From being used for exclusive purposes only,
neuroimaging is now in the forefront of aiding in the
diagnosis of Alzheimer's disease (AD), frontotemporal
dementia, vascular dementia, and and dementia with
Lewy bodies (DLB). With the exception of dopamine
transporter single photon-emission computed tomogra-
phy imaging in DLB, imaging has not yet been incorpo-
rated into the diagnostic criteria for the various demen-
tia syndromes, but that will soon change. The recently
formulated research criteria for early AD recently formu-
lated by Dubois et al explicitly mention magnetic reso-
nance imaging and positron emission tomography for
AD, and are an example of a new diagnostic process
developing. In this review, the various imaging tech-
niques will be highlighted, with an emphasis on their
ability to diagnose Alzheimer's disease and separate it
from other entities. 
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:191-199.criteria published in 1984
1 are the most widely validated
and used. The criteria discern three categories of cer-
tainty: definite AD (established by postmortem or
biopsy), probable AD (Table I), and possible AD (when
there are other explanations for the cognitive syndrome
that are as likely). The average survival in AD is typically
about 8 to 13 years from the onset of symptoms.
Since the publication of the NINCDS-ADRDA criteria
in 1984, the elucidation of the biological basis of AD has
advanced inexorably, allowing a better understanding of
the disease process. The clinical phenotype of AD is no
longer described in exclusive terms, but can be character-
ized more definitively on a phenotypic basis. Distinctive
markers of the disease are now recognized, including
structural brain changes on magnetic resonance imaging
(MRI) with early and extensive involvement of the
medial temporal lobe, molecular neuroimaging changes
on positron emission tomography (PET) with hypome-
tabolism or hypoperfusion in temporoparietal areas, and
changes in cerebrospinal fluid (CSF) biomarkers. A dri-
ving force behind this emerging identity of AD has been
the intense research interest in characterizing the earli-
est stages of AD that predate the crossing of the demen-
tia threshold, defined by functional disability. From this,
a need was felt to identify prodromal AD that must be
distinguished within the broad and heterogeneous state
of cognitive functioning that falls outside normal aging
described by a wide range of nosological terms, including
Age-Associated Memory Impairment, Age-Related
Cognitive Decline, Age-Associated Cognitive Decline,
Mild Cognitive Disorder, Mild Neurocognitive Disorder,
Cognitively Impaired Not Demented, and Mild
Cognitive Impairment (MCI). This latter designation of
MCI has been the most widely used diagnostic label
referring to individuals who have subjective memory
and/or cognitive symptoms, objective memory and/or
cognitive impairment, and whose activities of daily living
are considered to be generally normal. Progression to
clinically diagnosable dementia occurs at a higher rate
from MCI than from normal, but is clearly not the invari-
able clinical outcome at follow-up. A more refined defi-
nition of AD is then required, to reliably identify individ-
uals with the disease at its earliest stages. A large group
of European and US investigators has formulated new
criteria for this earliest stage of AD, starting from the
presentation with a memory complaint in typical AD and
adding biomarker information from MRI, PET, or CSF
or genetic confirmation.
2 The proposed criteria are
detailed elsewhere in this issue (p 135).
Besides the typical neuropsychological profile of AD
presenting with early memory deficits as mentioned
above, there is evidence from clinico-neuropathological
studies that AD patients may present with different 
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Selected abbreviations and acronyms
AD Alzheimer's disease
CAA congophylic amyloid angiopathy
CBD corticobasal degeneration
CJD Creutzfeld-Jakob disease
CT computed tomography
DLB dementia with Lewy bodies
FTD frontotemporal dementia
MCI mild cognitive impairment
MRI magnetic resonance imaging
NPH normal-pressure hydrocephalus
OSAS obstructive sleep apnea syndrome
PA progressive aphasia
PET positron emission tomography
PSP progressive supranuclear palsy
SD semantic dementia
SPECT single proton emission computed tomography
VaD vascular dementia
Figure 1. Alternative image of AD: clock drawings by patients with AD.
In the clock-drawing test, the patient is asked to draw a clock
and set the time for 10 past 11.
1. Dementia established by clinical examination and confirmed by
neuropsychological tests
2. Deficits in two or more areas of cognition, including memory 
impairment
3. Progressive worsening of memory and other cognitive functions
4. No disturbances of consciousness
5. Onset between ages 40 and 90
6. Absence of systemic disorders or other brain disease that in 
and of themselves could account for the progressive deficits in 
memory and cognition
Table I. National Institute of Neurological and Communicative Disorders
and Stroke – Alzheimer's Disease and Related Disorders
Association (now Alzheimer's Association)—NINCDS-ADRDA—
criteria for probable Alzheimer's disease.neuropsychological profiles. These atypical variants of
AD suggest that the distribution of neuropathological
changes rather than the nature of the disease are
reflected in the clinical syndrome, and that in clinical
practice, the diagnosis of AD should be considered as a
diagnosis in a broad range of focal cognitive syndromes.
Of note, these atypical presentations are not captured in
the new research criteria,
2 which is acknowledged in the
article, but could mean that a substantial number of
patients will not be included in research projects. In Table
II some of the most striking atypical presentations are
mentioned. 
Differential diagnosis
Even when a patient fulfils clinical criteria as mentioned
in the previous paragraph, there is still a chance that the
patient has in fact a different underlying pathological
substrate. Some clinical features may hint at a different
neuropathological substrate and render the clinical diag-
nosis of AD less likely. In Table III these clinical features,
or “red flags,” are listed, with the other diagnostic consid-
erations listed alongside.
Neuroimaging
Computed tomography and and magnetic resonance
imaging
The microscopic histological changes in the neurodegen-
erative diseases are inevitably associated with progres-
sive regional and global brain atrophy, which may be
assessed in vivo using MRI. In AD, focal atrophy in the
medial temporal lobe region, including the hippocampus,
has been the focus of extensive study. It reflects the typ-
ical pattern of progression of neuropathology, spreading
from the entorhinal cortex and hippocampus to the asso-
ciation cortices, as described by Braak and Braak.
4
Neuropathological studies have shown that hippocampal
volumes, as measured using MRI, correlate well with the
neuropathological burden at postmortem. Many studies
initially using computed tomography (CT) and later MRI
and more recently again using multislice CT have
assessed the diagnostic value of hippocampal atrophy for
AD. In a meta-analysis of studies using visual and linear
measurements of medial temporal lobe atrophy (MTA)
on MRI, the overall sensitivity and specificity for detec-
tion of AD compared with controls was estimated to be
85% and 88%, respectively.
5 In clinical practice simple
visual rating scales estimating hippocampal atrophy have
proven to be useful. Many authors have designed these
scales, and as long as volumetry lacks standardization and
operationalization between laboratories and clinics, these
scales will be around for some time. 
A striking example of medial temporal lobe atrophy is
shown in Figure 2. 
In clinical practice evaluation of the pattern of atrophy
of the entire brain should be taken into account, rather
than an isolated evaluation of the medial temporal lobe.
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￿ Balint’s like syndrome (optic ataxia, simultanagnosia, 
optic apraxia)
￿ Aperceptive visual agnosia
￿ Fluent or nonfluent aphasia
￿ Limb apraxia
￿ Visual disorientation and navigation problems
￿ Behavioral disturbances resembling frontotemporal dementia
Table II. Atypical presentations of Alzheimer's disease.
Red flag
Abrupt onset
Stepwise deterioration
Prominent behavioral 
changes
Profound apathy
Prominent aphasia
Progressive gait disorder
Prominent fluctuations in 
level
-of consciousness
-or cognitive abilities
Hallucinations or delusions
Frequent falls
Extrapyramidal signs or 
gait problems
Rapid decline
Asymmetry in clinical signs
Eye-movement 
abnormalities
Alternative diagnosis
VaD
VaD
FTD, VaD
FTD, VaD
SD, PA, VaD
VaD, NPH
Delirium due to infection, 
medications, or other causes
DLB, Temporal lobe epilepsy, OSAS, 
metabolic disturbances
Delirium due to infection, 
medications, or other causes, DLB
DLB
PSP, DLB, Parkinsonian syndromes, 
VaD
CJD, DLB
CBD
PSP, Wernicke’s encephalopathy
Table III. Clinical red flags and alternative diagnostic considerations.
(See list of abbreviations at the beginning of this article)
Modified from ref 3: Kawas CH. Clinical practice. Early Alzheimer's disease. N Engl
J Med. 2003;349:1056-1063. Copyright © Massachussetts Medical Society 2003Usually, AD is characterized by global atrophy with
prominent atrophy of the medial temporal lobe.
However, atypical forms of AD have been described with
prominent posterior atrophy, especially prevalent among
younger AD patients (Figure 3). This entity has also been
designated as posterior cortical atrophy, but many stud-
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Figure 2. Coronal T1-weighted MRI scans of control (left) and patient with AD (right). Both subjects are 75 years old. The patient with AD shows
clear atrophy of the hippocampus.
Figure 3. AD patient with early onset (age 51). On the left pronounced parietal and posterior cingulate atrophy is seen, while in the right panel a coro-
nal cut of the same patient shows an intact medial temporal lobe.ies have shown that AD pathology is most often present.
This absence of hippocampal atrophy is one of the con-
spicuous findings in AD one can encounter. Other find-
ings and their associated proposed alternative diagnoses
are listed in Table IV.
Serial MR imaging
Besides the existence of regional atrophy, the most
important structural imaging feature of AD is progres-
sion of atrophy. A yearly decline in hippocampal volume
approximately 2.5 times greater in patients with AD than
in normal aged subjects is reported, and a relationship
exists between memory loss and hippocampal damage
across the spectrum from normal aging to dementia.
Neuroanatomical changes over time may be too mild, dif-
fuse, or topographically complex to be detected by sim-
ple visual inspection, or even with manually traced mea-
surements of regions of interest. New serial volumetric
imaging techniques developed in the last few years rep-
resent an added value to identify subtle structural brain
changes, which have brought extensive neocortical
changes to the fore, extending well beyond the medial
temporal lobe.
6
Vascular changes
Besides atrophy, cerebrovascular pathology has been
associated with AD, especially in the late onset form. As
such, overlap with vascular dementia (VaD) may occur
and patients may actually fulfil criteria for both AD and
VaD. Unfortunately, no operational criteria for so-called
mixed dementia exist, so it is left to the judgement of the
clinician, which label fits best with the clinical picture of
the patient. Further, use of PET or CSF may help to tease
out the relevant pathologies. 
In AD most often signs of small-vessel disease are pre-
sent on MRI in the form of white matter hyperintensities
(WMH), lacunar infarcts (lacunes) (Figures 4,5) and
microbleeds (Figure 6). Microbleeds have been associ-
ated with amyloid angiopathy, but their clinical relevance
is still uncertain.
Functional (molecular) imaging
Positron emission tomography
Brain metabolism can be studied using PET. Changes in
brain metabolism may precede structural brain changes.
Glucose metabolism can be visualized using the metabolic
tracer [18F]fluorodeoxyglucose (FDG). In AD, temporal,
parietal and most notably posterior cingular hypometab-
olism is found, discriminating AD patients from controls
with good discriminatory power (sensitivity and specificity
in the range of 85% to 90%, Figure 7). In current clinical
guidelines routine PET is not advised, since the added
Imaging in AD - Scheltens Dialogues in Clinical Neuroscience - Vol 11 . No. 2 . 2009
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Findings Consider alternative diagnoses
No hippocampal atrophy Normal aging; MCI; FTD, PSP, 
CBD
Unilateral hippocampal atrophy SD 
Extreme hippocampal atrophy SD; argyrophilic grain disease
Abundant small-vessel disease VaD; CAA; amyloid angiopathy
Unilateral cerebral atrophy CBD
No abnormalities Normal aging; early stage AD
Striking asymmetry temporal region SD, PA
Table IV. Conspicuous MRI/CT findings in patients suspected of having
AD. (See list of abbreviations at the beginning of this article)
Figure 4. Cerebrovascular pathology on axial fluid attenuated inversion
recovery (FLAIR) MRI scans. Confluent white matter changes
(Fazekas scale 3).Clinical research
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Figure 6. Microbleeds on Flash/T2*/2D axial MRI scan. On the left, predominantly in the basal ganglia; on the right, predominantly located cortically.
Figure 5. Cerebrovascular pathology on axial fluid attenuated inversion
recovery (FLAIR) MRI scans. Lacunar infarcts in basal ganglia on
both sides. 
Figure 7. Voxel-based analysis of FDG-PET of an AD patient compared
with normal controls. In red are the areas that are showing a
lower metabolism in the patient: posterior cingulate cortex and
bilateral parietal lobes as well as the temporal lobes. Courtesy
Dr Bart van Berckel, VUMC.value over clinical diagnosis and structural imaging has not
been demonstrated extensively.
Detecting amyloid in vivo using PET
An exciting novel application of PET is the in-vivo imag-
ing of amyloid. The amyloid β protein is considered
essential to the pathogenesis of AD, as it is the main con-
stituent of neuritic plaques – one of the neuropathologi-
cal hallmarks of AD.
After years of preclinical research, several amyloid-imag-
ing tracers have been introduced recently.
17,18 2-(1-{6-[(2-
18F-fluoroethyl)(methyl)amino]-2-naphtyl}ethylidene)malo
nitrile) (
18F-FDDNP) and N-methyl-
11C-2-(4’-methy-
laminophenyl)-6-hydroxy benzothiazole (
11C-PIB) have
been studied most extensively. Both tracers bind with
nanomolar affinity to amyloid: KD of 
18F-FDDNP and
11C-PIB are 0.75 and 1-2 nM, respectively.
7-9 Both trac-
ers enter the brain in amounts sufficient for imaging with
PET (Figure 8). Indeed, the first proof of concept studies
of 
11C-PIB and 
18F-FFDNP indicated that AD patients
showed increased retention of these tracers compared
with controls in areas known to contain large amounts of
amyloid deposits. 
7,9 However, the specific binding com-
ponent of 
11C-PIB is almost ninefold higher than that of
18F-FFDNP and the latter has substantial overlap with
binding in controls. As such, identification of pathologi-
cal amyloid load on an individual basis is possible with
11C-PIB but will prove to be difficult with 
18F-FFDNP, lim-
iting its clinical applicability.
10
Although the specific binding of 
11C-PIB has an excellent
effect size in AD patients, the clinical use of 
11C-PIB is
hampered by the short half-life of the radionuclide 
11C.
As an alternative, 
18F-PIB is currently undergoing clini-
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Figure 8. 
11C-PIB BPND images in the same AD patient as in Figure 3. Note the massive amyloid binding in red in almost the entire cortex. Courtesy of
Dr. B. Van Berckel, VUMCcal trials, and first results look promising. The longer half-
life of 
18F-PIB (110 minutes) compared with 
11C-PIB (20
minutes) enables studies at PET centers without an on-
site cyclotron, greatly increasing its clinical value. In addi-
tion, new 
18F-labeled ligands for amyloid imaging have
been published, such as 
18F-BAY94-9172
11, which also
have a good effect size and may become available for
clinical use within the coming years.
In vivo amyloid imaging may considerably add to our
understanding of the underlying pathophysiological
mechanisms of AD. Furthermore, imaging of amyloid
may prove to be a sensitive diagnostic marker, and
enable prognoses in the earliest stages of formation of
neuropathology.
12,13 It should be noted, however, that
amyloid deposition is not exclusively confined to AD, and
also occurs in dementia with Lewy bodies (DLB) and
congophylic amyloid angiopathy (CAA).
14
Single photon emission tomography 
Using single-photon emission computed tomography
(SPECT) one is able to get an impression of the regional
cerebral blood flow. The most widely used tracer is
99TcHMPAO. In typical AD cases a pattern resembling
the one seen on PET is seen: bilateral temporoparietal
hypoperfusion. The application of SPECT in clinical rou-
tine has been hampered by false-positive findings and
insufficient added value over MRI. More promising and
partly included in the routine clinical setting are neurore-
ceptor studies using 
123ioflupane(IFP)-CIT (DAT-scan)
which allows visualization of the degeneration of the
nigrostriatal dopaminergic neurons. Scintigraphically it
allows the distinction between patients with essential
tremor and patients with Parkinson’s disease or PSP and
MSA. In dementia the distinction between AD and DLB
may be relevant, especially when there are no extrapyra-
midal features. For this, the use of DAT is extremely help-
ful, showing abnormal findings in DLB and normal find-
ings in AD,
15,16 being superior to blood flow imaging with
HMPAO-SPECT. A 
123IIBZM-SPECT shows the
integrity of the postsynaptic dopamine receptor. It may
help in the distinction between idiopathic Parkinson’s
disease and diseases with parkinsonism like PSP and
MSA, although with low accuracy.
17
Conclusion
Neuroimaging is no longer optional in diagnosing the
underlying disease in dementia. Structural and functional
imaging techniques have evolved over time in terms of
resolution, availability, and costs. Imaging should always
be used in conjunction with the clinical findings and
never on its own. Some images are, however, diagnosti-
cally so evident that they often “make the case,” for
instance in SD and CBD. By far, the evidence for hip-
pocampal atrophy in AD exceeds that of the other imag-
ing modalities, probably closely followed by DAT scan-
ning for Parkinonistic disorders like DLB. Clinical
imaging findings are shown in Table V. The developments
in molecular imaging are moving at such a high speed
that amyloid imaging will not take long before entering
the clinical arena. C-PIB, but maybe even earlier a fluo-
ride version of PIB or 
18F-BAY94-9172, are the most
likely candidates for this. Using all these techniques, we
are slowly entering the phase in which it will be possible
to diagnose AD before dementia occurs.  ❏
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Option Modality Result
Rule out structural lesion CT=MRI Tumor, hydrocephalus, subdural hematoma
Hippocampal atrophy MRI>CT Symmetric atrophy; slight asymmetry sometimes
Cerebral atrophy MRI>CT Biparietal atrophy; precuneus atrophy
White matter changes MRI>CT None to moderate changes, symmetric, frontal>parietal
Microbleeds MRI None to many, usually lobar
Lacunes MRI>CT None to a few, most often in subcortical white matter or basal ganglia
Hypometabolism FDG-PET Temporal, parietal, postcingular
Hypoperfusion SPECT=PET Biparietotemporal
Amyloid plaques PIB-PET>FDDNP PET Binding in frontal, temporal, and parietal lobes
Presynaptic dopaminergic neurons DAT-SPECT Less signal in striatum
Postsynaptic dopaminergic receptor IBZM-SPECT Less binding in striatum
Table V. Neuroimaging in AD: modalities and typical findings. =, modalities equally effective; >, one superior over the other. (See list of abbrevia-
tions at the beginning of this article)Imaging in AD - Scheltens Dialogues in Clinical Neuroscience - Vol 11 . No. 2 . 2009
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Imagenología en la Enfermedad de
Alzheimer
En la última década, las neuroimágenes han
ganado considerable interés para el diagnóstico
diferencial precoz de la demencia. Las neuroimáge-
nes, que inicialmente se utilizaron sólo con propó-
sitos exclusivos, actualmente están en primer plano
como ayuda para el diagnóstico de la Enfermedad
de Alzheimer (EA), la demencia frontotemporal, la
demencia vascular y la demencia por cuerpos de
Lewy (DCL). Con excepción de la tomografía com-
putada por emisión de fotón único (SPECT) que per-
mite identificar el transportador de dopamina en la
DCL, las neuroimágenes aun no han sido incorpo-
radas entre los criterios diagnósticos de los diversos
síndromes de demencia, pero esto cambiará pronto.
Los criterios de investigación para la EA precoz,
recientemente formulados por Dubois et al mencio-
nan explícitamente las imágenes de resonancia
magnética y de la tomografía por emisión de posi-
trones para la EA, y constituyen un ejemplo de un
nuevo proceso diagnóstico en desarrollo. En esta
revisión se destacarán las diversas técnicas de imá-
genes, con un énfasis en su capacidad para diagnos-
ticar Enfermedad de Alzheimer y separarla de otras
entidades. 
Neuro-imagerie dans la maladie d’Alzheimer
Ces 10 dernières années, le diagnostic différentiel
précoce de la démence par neuro-imagerie a acquis
ses lettres de noblesse. Utilisée auparavant à des
fins très spécifiques, la neuro-imagerie se place
maintenant à la pointe des technologies pour le
diagnostic de la maladie d’Alzheimer (MA), de la
démence frontotemporale, de la démence vascu-
laire et de la démence à corps de Lewy (DCL). Mis à
part le marquage par transporteur de dopamine en
tomographie par émission monophotonique
(TEMP) dans la DCL, l’imagerie n’est pas encore
entrée dans les critères diagnostiques des différents
syndromes démentiels, ce qui va bientôt changer.
Les critères de recherche récemment formulés pour
le diagnostic précoce de la MA recommandent de
façon explicite l’imagerie par résonance magné-
tique et la tomographie par émission de positrons
et sont un exemple du développement des nou-
velles techniques diagnostiques. Nous présenterons
dans cet article les différentes techniques
d’imagerie, en insistant sur leur aptitude à diagnos-
tiquer la MA et à la distinguer des autres patholo-
gies.
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